CLYYF
Price
$0.50
Change
-$0.15 (-23.08%)
Updated
May 30 closing price
Capitalization
16.94M
REPL
Price
$9.46
Change
-$0.00 (-0.00%)
Updated
Jun 27 closing price
Capitalization
719.22M
32 days until earnings call
Interact to see
Advertisement

CLYYF vs REPL

Header iconCLYYF vs REPL Comparison
Open Charts CLYYF vs REPLBanner chart's image
Celyad Oncology SA
Price$0.50
Change-$0.15 (-23.08%)
Volume$330
Capitalization16.94M
Replimune Group
Price$9.46
Change-$0.00 (-0.00%)
Volume$1.98K
Capitalization719.22M
CLYYF vs REPL Comparison Chart in %
Loading...
CLYYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CLYYF vs. REPL commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLYYF is a Hold and REPL is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (CLYYF: $0.50 vs. REPL: $9.46)
Brand notoriety: CLYYF and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLYYF: 77% vs. REPL: 0%
Market capitalization -- CLYYF: $16.94M vs. REPL: $719.22M
CLYYF [@Biotechnology] is valued at $16.94M. REPL’s [@Biotechnology] market capitalization is $719.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLYYF’s FA Score shows that 0 FA rating(s) are green whileREPL’s FA Score has 1 green FA rating(s).

  • CLYYF’s FA Score: 0 green, 5 red.
  • REPL’s FA Score: 1 green, 4 red.
According to our system of comparison, REPL is a better buy in the long-term than CLYYF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLYYF’s TA Score shows that 3 TA indicator(s) are bullish while REPL’s TA Score has 4 bullish TA indicator(s).

  • CLYYF’s TA Score: 3 bullish, 3 bearish.
  • REPL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, CLYYF is a better buy in the short-term than REPL.

Price Growth

CLYYF (@Biotechnology) experienced а 0.00% price change this week, while REPL (@Biotechnology) price change was +2.05% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

REPL is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($719M) has a higher market cap than CLYYF($16.9M). CLYYF YTD gains are higher at: 104.082 vs. REPL (-21.883).
CLYYFREPLCLYYF / REPL
Capitalization16.9M719M2%
EBITDAN/A-235.43M-
Gain YTD104.082-21.883-476%
P/E RatioN/AN/A-
RevenueN/A0-
Total CashN/A484M-
Total DebtN/A76.2M-
FUNDAMENTALS RATINGS
CLYYF vs REPL: Fundamental Ratings
CLYYF
REPL
OUTLOOK RATING
1..100
5081
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9998
PRICE GROWTH RATING
1..100
4658
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
1750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REPL's Valuation (26) in the Biotechnology industry is somewhat better than the same rating for CLYYF (81) in the null industry. This means that REPL’s stock grew somewhat faster than CLYYF’s over the last 12 months.

REPL's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLYYF (100) in the null industry. This means that REPL’s stock grew similarly to CLYYF’s over the last 12 months.

REPL's SMR Rating (98) in the Biotechnology industry is in the same range as CLYYF (99) in the null industry. This means that REPL’s stock grew similarly to CLYYF’s over the last 12 months.

CLYYF's Price Growth Rating (46) in the null industry is in the same range as REPL (58) in the Biotechnology industry. This means that CLYYF’s stock grew similarly to REPL’s over the last 12 months.

CLYYF's P/E Growth Rating (100) in the null industry is in the same range as REPL (100) in the Biotechnology industry. This means that CLYYF’s stock grew similarly to REPL’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CLYYFREPL
RSI
ODDS (%)
Bullish Trend 3 days ago
67%
N/A
Stochastic
ODDS (%)
N/A
Bullish Trend 3 days ago
83%
Momentum
ODDS (%)
Bullish Trend 3 days ago
41%
Bearish Trend 3 days ago
80%
MACD
ODDS (%)
Bullish Trend 3 days ago
42%
Bearish Trend 3 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
11%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
32%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
Bearish Trend 10 days ago
84%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
26%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CLYYF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CRZBY31.920.07
+0.23%
Commerzbank AG
CPNBQ0.06N/A
N/A
Telefonica Del Peru Sa
SJMHF0.34N/A
N/A
SJM Holdings Ltd.
KICK8.75N/A
N/A
HPN Holdings, Inc.
SALM0.87-0.07
-7.44%
Salem Media Group, Inc.

CLYYF and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLYYF has been loosely correlated with ELVAF. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CLYYF jumps, then ELVAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLYYF
1D Price
Change %
CLYYF100%
N/A
ELVAF - CLYYF
47%
Loosely correlated
N/A
WHWK - CLYYF
37%
Loosely correlated
+1.58%
HLVX - CLYYF
26%
Poorly correlated
+1.03%
REPL - CLYYF
25%
Poorly correlated
N/A
WXXWY - CLYYF
25%
Poorly correlated
N/A
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with IDYA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
N/A
IDYA - REPL
52%
Loosely correlated
-4.13%
SNDX - REPL
52%
Loosely correlated
-2.80%
XNCR - REPL
49%
Loosely correlated
-3.10%
CGON - REPL
48%
Loosely correlated
-0.46%
NRIX - REPL
47%
Loosely correlated
+0.17%
More